非ホジキンリンパ腫治療薬の市場規模、シェア、成長分析、治療の種類別、薬剤クラス別、投与経路別、適応症別、地域別 - 産業予測 2025年～2032年

非ホジキンリンパ腫治療薬の世界市場規模は2023年に52億米ドルと評価され、予測期間（2025-2032年）のCAGRは6.9%で、2024年の55億6,000万米ドルから2032年には94億8,000万米ドルに成長する見通しです。

世界の非ホジキンリンパ腫（NHL）治療薬市場は、主に高齢化と早期発見を可能にする診断技術の進歩によるNHL罹患率の上昇に牽引され、大きな成長を遂げています。このような患者数の増加は、効果的な治療に対する需要の高まりにつながり、製薬会社やヘルスケアプロバイダーは新たな治療法の開発に注力するようになっています。さらに、研究開発への投資も急増し、市場の拡大を促しています。特筆すべき動向は免疫療法、特にキメラ抗原受容体（CAR）T細胞療法の進歩であり、がん細胞を効果的に標的とし破壊します。これらの革新的な治療は患者の予後を改善し、個別化レジメンへのシフトを促進し、非ホジキンリンパ腫治療薬セクターの成長をさらに促進しています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

非ホジキンリンパ腫治療薬市場規模：治療の種類別& CAGR（2025-2032）

• 市場概要
• 化学療法
• 免疫療法
• 標的療法
• 放射線治療

非ホジキンリンパ腫治療薬市場規模：薬剤クラス別& CAGR（2025-2032）

• 市場概要
• モノクローナル抗体
• 化学療法剤
• ブルトン型チロシンキナーゼ阻害剤
• 免疫調節薬

非ホジキンリンパ腫治療薬市場規模：投与経路別& CAGR（2025-2032）

• 市場概要
• 静脈内
• 経口
• 皮下

非ホジキンリンパ腫治療薬市場規模：適応症別& CAGR（2025-2032）

• 市場概要
• びまん性大細胞型B細胞リンパ腫
• 濾胞性リンパ腫
• マントル細胞リンパ腫
• バーキットリンパ腫

非ホジキンリンパ腫治療薬市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024年）

主要企業プロファイル

• Roche（Switzerland）
• Novartis（Switzerland）
• Gilead Sciences（USA）
• Bristol-Myers Squibb（USA）
• AbbVie（USA）
• Merck & Co.（USA）
• AstraZeneca（United Kingdom）
• Sanofi（France）
• Bayer AG（Germany）
• Johnson & Johnson（USA）
• Pfizer（USA）
• Eli Lilly and Company（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Genmab（Denmark）
• Seagen Inc.（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Kyowa Kirin Co., Ltd.（Japan）
• Spectrum Pharmaceuticals Inc.（USA）
• Autolus Therapeutics（UK）
• Immuneel Therapeutics Private Limited（India）

結論と提言

Global Non-Hodgkin Lymphoma Therapeutics Market size was valued at USD 5.2 billion in 2023 and is poised to grow from USD 5.56 billion in 2024 to USD 9.48 billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).

The global Non-Hodgkin Lymphoma (NHL) therapeutics market is experiencing significant growth, driven by the rising incidence of NHL, primarily due to an aging population and advancements in diagnostic technologies that enable earlier detection. This increasing patient base is resulted in a higher demand for effective treatments, prompting pharmaceutical companies and healthcare providers to focus on developing new therapeutic options. Additionally, there is a surge in research and development investments, stimulating market expansion. A notable trend is the advancement of immunotherapy, particularly Chimeric Antigen Receptor (CAR) T-cell therapies, which effectively target and destroy cancer cells. These innovative treatments improve patient outcomes, fostering a shift toward personalized regimens and further fueling growth within the NHL therapeutics sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Non-Hodgkin Lymphoma Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Non-Hodgkin Lymphoma Therapeutics Market Segments Analysis

Global Non-Hodgkin Lymphoma Therapeutics Market is segmented by Therapeutic Type, Drug class, Administration Route, Indication and region. Based on Therapeutic Type, the market is segmented into Chemotherapy, Immunotherapy, Targeted Therapy and Radiation Therapy. Based on Drug class, the market is segmented into Monoclonal Antibodies, Chemotherapeutic Agents, Bruton's Tyrosine Kinase Inhibitors and Immunomodulators. Based on Administration Route, the market is segmented into Intravenous, Oral and Subcutaneous. Based on Indication, the market is segmented into Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma and Burkitt Lymphoma. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Non-Hodgkin Lymphoma Therapeutics Market

The global non-Hodgkin lymphoma therapeutics market is primarily driven by the rising incidence of non-Hodgkin lymphoma, largely attributed to an aging population and various lifestyle factors. As the number of diagnoses continues to climb, there is an escalating need for advanced treatment solutions, including immunotherapies, chemotherapy, and targeted therapies. This heightened demand for innovative treatment options not only reflects the urgency in addressing patients' needs but also propels significant growth in the market, further encouraging research and development efforts aimed at improving patient outcomes and expanding therapeutic possibilities in combating this form of cancer.

Restraints in the Global Non-Hodgkin Lymphoma Therapeutics Market

The growth of the Global Non-Hodgkin Lymphoma Therapeutics market faces substantial obstacles, particularly in developing regions where there is a limited understanding of non-Hodgkin lymphoma. The challenges associated with early diagnosis significantly impede market progression, as insufficient healthcare infrastructure and lack of diagnostic resources create delays in identifying and treating the condition. This lack of timely intervention adversely impacts the demand for therapeutic options, ultimately constraining market expansion in these underserved areas. Addressing these awareness and infrastructure gaps is crucial for enabling better access to treatments and enhancing market potential in the long term.

Market Trends of the Global Non-Hodgkin Lymphoma Therapeutics Market

The Global Non-Hodgkin Lymphoma (NHL) therapeutics market is experiencing a significant shift towards immunotherapy, particularly with the rise of CAR-T cell therapies. This innovative approach leverages the body's immune response to effectively target and eliminate lymphoma cells, showing remarkable efficacy in patients with relapsed or refractory cases. The increasing approval of these advanced therapies, coupled with ongoing research and clinical trials, underscores a growing acceptance and demand within the healthcare community. As a result, the market is projected to expand rapidly, driven by enhancements in treatment outcomes, patient quality of life, and the potential for personalized medicine strategies in NHL management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Non-Hodgkin Lymphoma Therapeutics Market Size by Therapeutic Type & CAGR (2025-2032)

• Market Overview
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Radiation Therapy

Global Non-Hodgkin Lymphoma Therapeutics Market Size by Drug class & CAGR (2025-2032)

• Market Overview
• Monoclonal Antibodies
• Chemotherapeutic Agents
• Bruton's Tyrosine Kinase Inhibitors
• Immunomodulators

Global Non-Hodgkin Lymphoma Therapeutics Market Size by Administration Route & CAGR (2025-2032)

• Market Overview
• Intravenous
• Oral
• Subcutaneous

Global Non-Hodgkin Lymphoma Therapeutics Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Diffuse Large B-Cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Burkitt Lymphoma

Global Non-Hodgkin Lymphoma Therapeutics Market Size & CAGR (2025-2032)

• North America (Therapeutic Type, Drug class, Administration Route, Indication)
  • US
  • Canada
• Europe (Therapeutic Type, Drug class, Administration Route, Indication)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapeutic Type, Drug class, Administration Route, Indication)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapeutic Type, Drug class, Administration Route, Indication)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapeutic Type, Drug class, Administration Route, Indication)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genmab (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seagen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kyowa Kirin Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spectrum Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Autolus Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immuneel Therapeutics Private Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations